Amicus raises $60 million in series D round

By Elaine Rigoli

Tampa, Fla., Sept. 14 - Amicus Therapeutics, Inc. has closed a $60 million series D financing round, the company's largest to date, led by New Enterprise Associates, Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, Palo Alto Investors, Prospect Venture Partners, Quaker BioVentures and Radius Ventures.

Affiliated investment funds of Och-Ziff Capital Management Group also participated in this round of financing as new investors.

Amicus also announced two key executive management appointments:

• Donald J. Hayden, executive chairman, will become interim president and chief executive officer while president and chief executive officer John F. Crowley fulfills a six-month active duty military obligation with the U.S. Navy due to end in March 2007.

• Matthew R. Patterson was promoted to chief operating officer from chief business officer.

Amicus is a biopharmaceutical company based in Cranbury, N.J.

Issuer: Amicus Therapeutics, Inc.

Issue: Series D financing

Amount: $60 million

Investors: New Enterprise Associates, Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, Palo Alto Investors, Prospect Venture Partners, Quaker BioVentures, Radius Ventures, funds affiliated with Och-Ziff Capital Management Group

Announcement date: Sept. 14

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.